RealSense has formally spun out from Intel and raised $50 million in Series A funding to ramp up growth in AI‑driven vision solutions for robotics and biometrics.
Supported by Intel Capital, MediaTek Innovation Fund and other strategic investors, the business is now free-standing and set to scale up production and grow its international operations. Its depth cameras are already deployed in approximately 60 percent of autonomous mobile robots and humanoids around the globe.
Health Technology Insights: Johnson & Johnson Seeks EMA Approval to Extend AKEEGA Use for Prostate Cancer
CEO Nadav Orbach emphasized the opportunity ahead. “We’re excited to build on our leadership position in 3D perception in robotics and see scalable growth potential in the rise of physical AI,” said Orbach. He also noted the D555 depth camera’s recent enhancements, including single‑cable power and data support and embedded AI for autonomous navigation and security systems. RealSense plans to invest heavily in AI software development and new camera technologies.
Health Technology Insights: AAMI Aligns With National Academy of Medicine AI Code of Conduct
The spin‑out comes after more than a decade of development within Intel and signals a transition to agile operations under an independent organization. With over 3 000 active customers such as Unitree Robotics and ANYbotics and increasing presence in facial recognition and access control, RealSense is poised to drive innovation in computer vision. Orbach indicated that although the firm is still privately owned, an IPO or acquisition would be feasible in the future.
Health Technology Insights: ACA Pharma Secures Fast-track Approval For Eagle Pharmaceuticals’ Ryanodex In Macau
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
